Literature DB >> 7302543

[Amiodarone and the thyroid gland].

M Stäubli, P Bischof, C Wimpfheimer, H Studer.   

Abstract

In an estimated 5% of patients, antiarrhythmic therapy with amiodarone (Cordarone) may have side effects involving thyroid function. These unwanted effects on the thyroid gland can be classified into three entirely different categories. In addition, amiodarone invariably interferes in a characteristic way with the peripheral metabolism of thyroid hormones at the cellular level. These effects are reviewed. 1. Amiodarone contains 39% of iodine. Since its metabolism involves deiodination to inorganic iodide, classical iodine-induced thyrotoxicosis may occur in patients with nodular goiters containing autonomous follicles. 2. An entirely different form of thyrotoxicosis, resembling Graves' disease, may be induced by amiodarone in individuals with previously normal thyroid. The pathogenesis of this phenomenon is unknown. 3. In rare patients of the thyroid gland is unable to cope with pharmacological quantities of iodide, possibly due to genetic anomaly of thyroid metabolism. In these individuals amiodarone may induce hypothyroidism. 4. In contrast to the possible side effects of amiodarone involving the thyroid gland, the drug has an obligate impact on the metabolism of thyroid hormones at the level of the peripheral cells. It inhibits the peripheral conversion of thyroxin to triiodothyronine (T3) and favours the generation of reverse T3, which has no T3 activity. This and other arguments favour the assumption that the effects on the heart observed after prolonged amiodarone treatment are in fact due to selective local hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7302543

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  5 in total

1.  Amiodarone and thyroid hormone metabolism.

Authors:  W M Wiersinga; M D Trip
Journal:  Postgrad Med J       Date:  1986-10       Impact factor: 2.401

2.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites.

Authors:  M Stäubli; A Troendle; B Schmid; P Balmer; B Kohler; H Studer; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  The clinician and the thyroid.

Authors:  H J Biersack; A Hotze
Journal:  Eur J Nucl Med       Date:  1991

5.  Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis.

Authors:  M Stäubli; H Studer
Journal:  Klin Wochenschr       Date:  1985-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.